A. Kotsakis, Ph. Koinis
Chairs: N. Tsoukalas, A. Tzovaras
12.00-12.20 Abstract 12000: Impact of acetaminophen on the efficacy of immunotherapy in cancer patients
Abstract 12023: Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221
Al. Lazarou
12.20-12.40 Abstract 507: Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial
Abstract 8504: Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702)
F. Folinas
12.40-13.00 Abstract 6501: The PACES Study: A controlled before and after pragmatic trial of a cancer clinic based intervention to increase early referral to specialist palliative care
Abstract 6500: The effect of a multilevel community health worker-led intervention on health-related quality of life, patient activation, acute care use, and total costs of care: A randomized controlled trial
D. Papageorgiou
13.00-13.15 Discussion
Chairs: L. Florentin, E. Saloustros
13.15-13.45 Abstract 5007: Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management
Abstract 10501: Rates of germline genetic testing and DNA damage response mutations found through population-based recruitment of men with incident metastatic prostate cancer
Abstract 10502: Mutation spectrum and rates of variants of uncertain significance among African American males undergoing prostate cancer germline testing: Need for equity in genetic testing
A. Assi
13.45-14.00 Discussion
Light Lunch
Chairs: Ε. Razis, G. Rigakos
15.00-15.20 Abstract 2006: Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation
Abstract 2001: Randomized phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma (GBM) patients with MGMT promoter hypermethylation (Alliance A071102)
A. Tsiara
15.20-15.40 Abstract LBA 2002: Primary analysis of a phase II trial of dabrafenib + trametinib (dab + tram) in BRAF V600-mutant pediatric low-grade glioma (pLGG)
Abstract 2003: Prognostic validation and refinement of a classification system for extent of resection in glioblastoma: A report of the RANO resect group
S. Talagani
15.40-16.00 Discussant E. Razis
Chairs: A. Stribakos, L. Vamvakas
At the Intersection of Biomarkers and Health Equity for Older Adults With Cancer
Ch. Panopoulos
Chairs: Ch. Andreadis, A. Kotsakis
16.30-16.50 Abstract 6015: Refining nodal category in TNM staging with extent of extranodal extension for oral cavity squamous cell carcinoma
Abstract 6000: Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised phase III trial
P. Katsaounis
16.50-17.10 Abstract 6004: An open label non-inferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial)
Abstract 6006: Association of plasma tumor tissue modified viral HPV DNA (TTMV) with tumor burden, treatment type, and outcome: A translational analysis from NRG-HN002.
E. Biziota
17.10-17.20 Discussant A. Psyrri
Coffee Break
Chairs: Ch. Cristodoulou, D. Tryfonopoulos
17.40-18.25 Abstract 500: Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial
Abstract LBA501: LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC)
Abstract 506: Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial
K. Rapti
18.25-18.40 Discussant A. Matikas
Chairs: V. Barbounis, Th. Foukakis
18.40-19.10 Abstract 504: Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial
Abstract LBA3: Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study
Abstract LBA1001: Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/ HER2-Negative (HR+/HER2-) Advanced Breast Cancer
S. Karageorgopoulou
19.10-19.30 Abstract LBA1004: A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial
Abstract 1005: Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free survival data with enhanced biomarker analysis.
V. Aidarinis
19.30-19.50 Discussant E. Galani
Chairs: M. Nikolaou, N. Xenidis
09.00-09.30 Abstract 2501: First-in-human study of SRF388, a first-in-class IL-27 targeting antibody, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors
Abstract 2505: Phase 1 first-in-human study of anti–ILT3 mAb MK-0482 as monotherapy and in combination with pembrolizumab in advanced solid tumors: Dose escalation results
Abstract 2506: A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors
E. Kontopodis
09.30-09.40 Discussion
Chairs: O. Katopodi, G. Papaxoinis
09.40-10.00 Abstract LBA100: Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial
Abstract LBA5: Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer
N. Vardakis
10.00-10.20 Abstract LBA1: Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): results from the phase 3 PARADIGM trial
Abstract 3503: Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer
A. Markou
10.20-10.40 Abstract LBA 4011: Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter and phase III clinical trial
Abstract 4006: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial)
I. Samaras
10.40-11.00 Discussant G. Papaxoinis
Chairs: I. Athanasiadis, M. Liontos
Small Molecule Inhibition of KRAS: Opportunities and Challenges
V. Papadopoulos
Chairs: D. Bafaloukos, D. Ziogas
12.00-12.20 Abstract LBA 9500: Distant metastasis-free survival with pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: the phase 3 KEYNOTE-716 study
Abstract 9502: Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512).
J. Duran - Moreno
12.20-12.40 Abstract 9505: Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047
Abstract 9507: Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers
Aik. Kotsori
12.40-13.00 Discussant. A. Laskarakis
Chairs: S. Fortis, I. Pateras
Beyond Checkpoint Inhibitors: Next-Generation Immunotherapies
A. Boutis
Light Lunch
Chairs: V. Karavasilis, G. Kesisis
14.30-14.50 Abstract LBA2: Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)
Abstract 101: Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST)
S. Kokkali
14.50-15.10 Abstract 11500: Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS)
Abstract 11506: A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates
A. Kyriazoglou
15.10-15.30 Discussant V. Karavasilis
Chairs: Ch. Papadimitriou, V. Papadopoulos
15.30-15.50 Abstract LBA5500: ATHENA-MONO: A randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment following response to frontline platinum-based chemotherapy in ovarian cancer
Abstract 5512: Mirvetuximab sorvatansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha: FRa expression: characterization of antitumor activity in the SORAYA study
M. Rovithi
15.50-16.10 Abstract 5509: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
Abstract 5507: Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
M. Drizou
16.10-16.30 Discussant. R. Zakopoulou
Coffee Break
Chairs: H. Kotteas, G. Oikonomopoulos
17.00-17.30 Abstract LBA8507: SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC)
Abstract 8500: Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial Abstract 8512: EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): Outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use
E. Eleutherakis - Papaiakovou
17.30-18.00 Abstract 9000: Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis
Abstract 9004: Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: Lung-MAP non-matched sub-study S1800A
Abstract 102: Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100
D. Stefanou
18.00-18.30 Discussant An. Grivas
Chairs: E. Lianos, K. Tsapakidis
18.30-18.50 Abstract LB4500: EVEREST: EVErolimus for Renal cancer Ensuing Surgical Therapy, A phase III study
Abstract 4513: Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426
Abstract 4502: The relationship between health-related quality of life (HRQoL) and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) in CheckMate (CM) 214
Th. Tegos
18.50-19.10 Discussant K. Koutsoukos
Chairs: Ph. Koinis, Ch. Kourousis, M. Tsiatas
19.10-19.40 Abstract 4516: Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Abstract LBA 5004: Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)
Abstract 5000: TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Overall survival aftermedian follow-up of 3 years (ANZUP 1603)
N. Asimakopoulou
19.40-20.00 Discussan M. Tsiatas
Closing Remarks